Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Otsuka, UCB Tie Up for Keppra and Cimzia in Japan
June 23, 2008
- R&D NEWS IN BRIEF -2-
June 23, 2008
- Asahi Kasei Pharma Licenses Treatment for Osteoarthritis
June 23, 2008
- MEDICAL DEVICE NEWS IN BRIEF
June 23, 2008
- Pfizer Beefs Up Promotion of Norvasc
June 23, 2008
- SELF-MEDICATION NEWS IN BRIEF
June 23, 2008
- Diovan Stays No. 1 for 3 Months in a Row: Rep Track Survey
June 23, 2008
- SEMINARS
June 23, 2008
- BUSINESS NEWS IN BRIEF
June 23, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -1-
June 23, 2008
- Yamato HD Proposes Direct Deal between Makers and Med. Institutions
June 23, 2008
- Daiichi Sankyo to Acquire Majority of Ranbaxy Shares
June 23, 2008
- Increase Share of Generics to 40%: Council
June 23, 2008
- GENERICS NEWS IN BRIEF
June 23, 2008
- FPMAJ Report on FY2008 NHI Price Revision
June 23, 2008
- Record-High 81 Applications Approved in FY2007
June 23, 2008
- REGULATORY NEWS IN BRIEF
June 23, 2008
- Nippon Shinyaku to Include RNA Drug Candidates in Its R&D Pipeline within 2 Years
June 23, 2008
- AnGes MG to Develop Gene Therapy for Mucopolysaccharidosis VI
June 23, 2008
- CRO Business Pulls CMIC with 19.6% Increase in Sales
June 16, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…